Executive Briefings

BioPharma Asia Convention 2016

22 - 24 March 2016, Suntec International Convention & Exhibition Centre Contact: Lydia Sebastian Tel: +65 6322 2750 Email: Lydia.sebastian@terrapinn.com

The 9th annual Biopharma Asia Convention 2016 brings together C-level attendees from pharmas, biotecs and service providers to learn and discuss market trends and biologic development strategies.

Asia's biopharma industry is growing, and growing fast. With technical expertise, low manufacturing costs and improving regulatory frameworks, its value will soon run into the hundreds of billions of dollars. Are you making the most of the opportunity?

Welcome to BioPharma Asia 2016. From humble beginnings as BioMedical Asia in 2008, BioPharma Asia has attracted close to 20,000 attendees over the last 8 years. Established as a true one-stop shop for all things biopharma, our 2016 program will be bigger than ever before, offering you more tracks, more content and more value. Our 7 premium conference tracks will explore innovation in clinical trials, manufacturing, supply chain, market access, partnering, pricing, vaccines & infectious diseases, antibodies, orphan drugs, biosimilars, stem cells and more.

A sample of who is speaking includes:

  • Alan Bollard, Executive Director, Asia-Pacific Economic Corporation (APEC) Secretariat, Singapore
  • Ali Miserez, Nanyang Assistant Professor, NRF Fellow, Nanyang Technology University, Singapore
  • Badri Rengarajan, President, International Pemphigus & Pemphigoid Foundation, USA
  • Carlos Pereira, Site Head, Manufacturing, Novartis, Singapore
  • Churn Shiouh Gau, Chief Executive Director, Center for Drug Evaluation, Taiwan
  • Deborah Elms, Executive Director, Asian Trade Centre, Singapore
  • Dimiter Dimitrov, Senior Investigator, Head of Protein Interactions Section, NIH, USA
  • Hugh Davis, Vice President, Head, Biologics Clinical Pharmacology and China Biologics Leader, Biotechnology CoE, Janssen, USA
  • Jian Li, Director, Partnering and External Innovation, Asia Pacific, Sanofi, China
  • Jin-Hyung Shim, Assistant Professor, Korea Polytechnic University, Korea
  • Jun Wang, Founder, Executive Director, Beijing Genome Institute (BGI), China
  • Weng Si Ho, Executive Director, Biomedical Sciences and Consumer Business, Singapore Economic Development Board, Singapore
  • Koichi Miyazaki, Senior Director, Regulatory Affairs Group, Asia Development Department, R&D Division, Daiichi-Sankyo, Japan
  • Lucas Chan, Head, Advanced Therapy Production, NIHR Investigator in Cell and Gene therapy, King’s College Hospital Clinical Research Facility, UK
  • Luke Alphey, Group Leader, Vector-borne Viral Diseases, The Pirbright Institute, UK
  • Maggie Lim, Clinical Compliance Director, Asia Pac, Japan and EM, GlaxoSmithKline, Singapore
  • Mary Tai, Deputy Director, Division of Medicinal Products, FDA, Taiwan
  • Matej Ondrus, Medical Director, AXON Neuroscience, Slovakia
  • Niven R. Narain, Co-Founder, President, Chief Technology Officer, BERG Pharma, USA
  • Paolo Rampichini, Head, Supply Chain Asia Pacific, Roche, Singapore
  • Pele Chong, Director, Vaccines Research and Development Center, National Health Research Institute, Taiwan
  • Peter Senter, Vice President, Chemistry, Seattle Genetics, USA
  • Prabhuram Krishnan, Medical Director, Eli Lilly, Malaysia
  • Roman Ivanov, R&D Director, BIOCAD, Russia 
  • Ronan McGarvey, Director, Quality Operations, AbbVie, Singapore
  • Sannie Chong, APAC Technical Regulatory Policy, Genentech, a member of Roche, Singapore
  • Satish Jindal, CEO, Allied-Bristol Life Sciences, USA
  • Shailendra Bajpai, Regional Medical Director, Diabetes Asia, Sanofi- Aventis, Singapore
  • Shao Siong Chua, Head of Manufacturing, Baxalta, Singapore
  • Silviu Itescu, CEO and Managing Director, Mesoblast, Australia
  • St John Donnie Mcgrath, Vice President, Executive Director, Bristol Myers Squibb, USA
  • Stewart Geary, Senior Vice President, Chief Medical Officer, General Manager, Corporate Medical Affairs Headquarter, Eisai Co. Ltd, Japan
  • TianLei Ying, Professor, Fudan University, China
  • William WeiGuo Jia, Associate Professor, Neurosurgery Research, The University of British Columbia, Canada
  • Yoshiya Oda, President, Biomarkers and Personalised Medicine, Eisai Inc, USA
  • Zelig Eshhar, Chairman, Department of Immunology, Weizmann Institute, Israel

Want to know who else is speaking? Click here

Download the brochure for more information

The 9th annual Biopharma Asia Convention 2016 brings together C-level attendees from pharmas, biotecs and service providers to learn and discuss market trends and biologic development strategies.

Asia's biopharma industry is growing, and growing fast. With technical expertise, low manufacturing costs and improving regulatory frameworks, its value will soon run into the hundreds of billions of dollars. Are you making the most of the opportunity?

Welcome to BioPharma Asia 2016. From humble beginnings as BioMedical Asia in 2008, BioPharma Asia has attracted close to 20,000 attendees over the last 8 years. Established as a true one-stop shop for all things biopharma, our 2016 program will be bigger than ever before, offering you more tracks, more content and more value. Our 7 premium conference tracks will explore innovation in clinical trials, manufacturing, supply chain, market access, partnering, pricing, vaccines & infectious diseases, antibodies, orphan drugs, biosimilars, stem cells and more.

A sample of who is speaking includes:

  • Alan Bollard, Executive Director, Asia-Pacific Economic Corporation (APEC) Secretariat, Singapore
  • Ali Miserez, Nanyang Assistant Professor, NRF Fellow, Nanyang Technology University, Singapore
  • Badri Rengarajan, President, International Pemphigus & Pemphigoid Foundation, USA
  • Carlos Pereira, Site Head, Manufacturing, Novartis, Singapore
  • Churn Shiouh Gau, Chief Executive Director, Center for Drug Evaluation, Taiwan
  • Deborah Elms, Executive Director, Asian Trade Centre, Singapore
  • Dimiter Dimitrov, Senior Investigator, Head of Protein Interactions Section, NIH, USA
  • Hugh Davis, Vice President, Head, Biologics Clinical Pharmacology and China Biologics Leader, Biotechnology CoE, Janssen, USA
  • Jian Li, Director, Partnering and External Innovation, Asia Pacific, Sanofi, China
  • Jin-Hyung Shim, Assistant Professor, Korea Polytechnic University, Korea
  • Jun Wang, Founder, Executive Director, Beijing Genome Institute (BGI), China
  • Weng Si Ho, Executive Director, Biomedical Sciences and Consumer Business, Singapore Economic Development Board, Singapore
  • Koichi Miyazaki, Senior Director, Regulatory Affairs Group, Asia Development Department, R&D Division, Daiichi-Sankyo, Japan
  • Lucas Chan, Head, Advanced Therapy Production, NIHR Investigator in Cell and Gene therapy, King’s College Hospital Clinical Research Facility, UK
  • Luke Alphey, Group Leader, Vector-borne Viral Diseases, The Pirbright Institute, UK
  • Maggie Lim, Clinical Compliance Director, Asia Pac, Japan and EM, GlaxoSmithKline, Singapore
  • Mary Tai, Deputy Director, Division of Medicinal Products, FDA, Taiwan
  • Matej Ondrus, Medical Director, AXON Neuroscience, Slovakia
  • Niven R. Narain, Co-Founder, President, Chief Technology Officer, BERG Pharma, USA
  • Paolo Rampichini, Head, Supply Chain Asia Pacific, Roche, Singapore
  • Pele Chong, Director, Vaccines Research and Development Center, National Health Research Institute, Taiwan
  • Peter Senter, Vice President, Chemistry, Seattle Genetics, USA
  • Prabhuram Krishnan, Medical Director, Eli Lilly, Malaysia
  • Roman Ivanov, R&D Director, BIOCAD, Russia 
  • Ronan McGarvey, Director, Quality Operations, AbbVie, Singapore
  • Sannie Chong, APAC Technical Regulatory Policy, Genentech, a member of Roche, Singapore
  • Satish Jindal, CEO, Allied-Bristol Life Sciences, USA
  • Shailendra Bajpai, Regional Medical Director, Diabetes Asia, Sanofi- Aventis, Singapore
  • Shao Siong Chua, Head of Manufacturing, Baxalta, Singapore
  • Silviu Itescu, CEO and Managing Director, Mesoblast, Australia
  • St John Donnie Mcgrath, Vice President, Executive Director, Bristol Myers Squibb, USA
  • Stewart Geary, Senior Vice President, Chief Medical Officer, General Manager, Corporate Medical Affairs Headquarter, Eisai Co. Ltd, Japan
  • TianLei Ying, Professor, Fudan University, China
  • William WeiGuo Jia, Associate Professor, Neurosurgery Research, The University of British Columbia, Canada
  • Yoshiya Oda, President, Biomarkers and Personalised Medicine, Eisai Inc, USA
  • Zelig Eshhar, Chairman, Department of Immunology, Weizmann Institute, Israel

Want to know who else is speaking? Click here

Download the brochure for more information